, Singapore
1995 views
Photo by National Cancer Institute from Unsplash

SAM Holdings and EnGeneIC partner to produce EDV-based anti-cancer products

The SGX-listed company gained exclusive global rights for EnGeneIC's EDV theranostics.

The Singapore Institute of Advanced Medicine Holdings (SAM Holdings) and EnGeneIC have formed a strategic partnership to revolutionise the cancer treatment landscape in Asia and provide better outcomes of life for patients. 

The partners will collaborate on a profit-sharing basis to produce EDV-based anti-cancer products and develop theranostics for cancer imaging and treatment.

SAM Holdings will help EnGeneIC secure funding and regulatory approvals for building a Singapore plant to manufacture EDV-based products, conduct clinical trials, and obtain marketing authorisation. 

In turn, SAM Holdings will receive exclusive distribution and marketing rights in 17 Asian countries.

In addition, SAM Holdings will work with EnGeneIC on pre-clinical testing and regulatory approval of EDV-based theranostics and receive exclusive worldwide distribution rights for these theranostics.

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.